title: Memantine's action against aminoglycoside-induced ototoxicity.
abstract: The objectives of this study were (1) to assess the protective role of NMDA antagonists against the ototoxic effects of aminoglycosides, (2) to provide any possible evidence between ototoxicity due to aminoglycosides and excitotoxicity. An animal experiment was conducted. Twenty-eight, 3-month-old female New Zealand rabbits, weighing 1,000-1,500 g, were studied prospectively for 28 days after intramuscular administration of amikacin (15 mg/kg/day divided into two equal doses) for 14 days. Twenty-one rabbits were categorized into three equal treatment groups and seven animals received no medication and served as the control group. The animals of A, B and C groups were injected, intramuscularly, with amikacin 15 mg/kg/day, divided into two equal doses every day for 14 days. Animals of group A received in parallel memantine (per os) and those of group B received p.o. the same volume of placebo solution. The rabbits of the third group (group C) received on the 15th day and every 2 days for the next 2 weeks, until the day 28, memantine of the same quantity as the members of group A. Differences in DPOAE amplitudes, and therefore in cochlear activity, between group A and group B were revealed. DPOAE amplitudes of group B were further reduced compared to the respective amplitudes in rabbits of group A. No improvement was observed in DPOAE measurements performed after the discontinuation of injections. The findings in group C should be examined separately. The measurements showed apparent reversal ototoxic effects in four of the animals. The development of aminoglycoside otoprotective strategies is a primary goal in ototoxicity research. The administration of NMDA antagonists has been shown to prevent, at least to some extent, toxic damage to hair cells in guinea pigs, treated with aminoglycoside antibiotics.
authors.affiliation: ENT Department, Katholisches Klinikum, Rudolf-Virchow-Str.7, 56073, Koblenz, Germany, papavlid@googlemail.com.
authors.forename: Pavlos
authors.initials: P
authors.lastname: Pavlidis
authors.forename: Jan
authors.initials: J
authors.lastname: Maurer
authors.forename: Eirini
authors.initials: E
authors.lastname: Apostolidou
authors.forename: Georgios
authors.initials: G
authors.lastname: Kekes
authors.forename: Dimitrios
authors.initials: D
authors.lastname: Kouvelas
mesh_terms: D000583:Amikacin / Q000633:toxicity*; D000617:Aminoglycosides / Q000633:toxicity*; D000818:Animals; D003051:Cochlea / Q000187:drug effects*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D005260:Female; D006309:Hearing / Q000187:drug effects; D034381:Hearing Loss / Q000139:chemically induced* / Q000517:prevention & control; D008559:Memantine / Q000494:pharmacology*; D017084:Otoacoustic Emissions, Spontaneous / Q000187:drug effects*; D011817:Rabbits
chemical_list: D000617:Aminoglycosides; D018691:Excitatory Amino Acid Antagonists; D000583:Amikacin; D008559:Memantine
references.citation: Audiol Neurootol. 2007;12(3):145-54
references.pmid: 17259700
references.citation: J Physiol. 1999 Aug 1;518 ( Pt 3):667-80
references.pmid: 10420005
references.citation: Nat Med. 1996 Dec;2(12):1338-43
references.pmid: 8946832
references.citation: Acta Otolaryngol Suppl. 1995;519:26-9
references.pmid: 7541931
references.citation: Int J Pediatr Otorhinolaryngol. 2010 Apr;74(4):361-4
references.pmid: 20089318
references.citation: Br Med Bull. 2002;63:223-41
references.pmid: 12324396
references.citation: Antimicrob Agents Chemother. 1994 Nov;38(11):2517-20
references.pmid: 7872740
references.citation: Annu Rev Pharmacol Toxicol. 1990;30:47-71
references.pmid: 2188577
references.citation: Otolaryngol Head Neck Surg. 1999 Dec;121(6):693-701
references.pmid: 10580222
references.citation: J Acoust Soc Am. 2002 Jan;111(1 Pt 1):285-96
references.pmid: 11831802
references.citation: Ear Hear. 1990 Apr;11(2):82-92
references.pmid: 2187727
references.citation: Nature. 1993 Aug 5;364(6437):535-7
references.pmid: 7687749
references.citation: J Acoust Soc Am. 2006 Aug;120(2):884-900
references.pmid: 16938977
references.citation: Laryngoscope. 2003 Sep;113(9):1615-22
references.pmid: 12972944
references.citation: Prog Neurobiol. 1995 Dec;47(6):449-76
references.pmid: 8787031
references.citation: J Clin Invest. 1986 May;77(5):1492-500
references.pmid: 3700652
references.citation: J Neurosci. 1992 Dec;12(12):4575-85
references.pmid: 1464757
references.citation: Ann Otol Rhinol Laryngol Suppl. 1990 May;147:3-14
references.pmid: 2110797
references.citation: Antimicrob Agents Chemother. 1989 Jun;33(6):797-800
references.pmid: 2669624
references.citation: Curr Neuropharmacol. 2010 Jun;8(2):128-34
references.pmid: 21119884
references.citation: Mol Pharmacol. 2001 Jul;60(1):183-9
references.pmid: 11408613
references.citation: J Assoc Res Otolaryngol. 2008 Mar;9(1):44-64
references.pmid: 18057986
references.citation: Science. 1985 Jan 11;227(4683):194-6
references.pmid: 3966153
references.citation: Neurosci Lett. 1995 Aug 4;195(2):137-9
references.pmid: 7478269
references.citation: Int J Dev Neurosci. 1997 Jul;15(4-5):619-29
references.pmid: 9263038
references.citation: Neuroscience. 2009 Dec 29;164(4):1854-66
references.pmid: 19778585
references.citation: Hear Res. 2005 Aug;206(1-2):200-26
references.pmid: 16081009
references.citation: J Neurosci. 1995 Mar;15(3 Pt 2):2338-53
references.pmid: 7891171
references.citation: Hear Res. 1988 Apr;33(1):69-93
references.pmid: 3372371